Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $130.00 at Royal Bank Of Canada

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target lowered by equities research analysts at Royal Bank Of Canada from $140.00 to $130.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 45.07% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. The Goldman Sachs Group lifted their target price on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Rhythm Pharmaceuticals in a research report on Tuesday, March 3rd. Needham & Company LLC dropped their price target on Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating on the stock in a report on Tuesday. Zacks Research raised Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Finally, Morgan Stanley reduced their price objective on Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $132.06.

Rhythm Pharmaceuticals Price Performance

Shares of NASDAQ RYTM traded down $0.90 during trading on Tuesday, hitting $89.62. The stock had a trading volume of 274,946 shares, compared to its average volume of 711,119. The firm has a fifty day moving average of $100.00 and a two-hundred day moving average of $102.91. The company has a market capitalization of $6.12 billion, a PE ratio of -28.82 and a beta of 2.06. Rhythm Pharmaceuticals has a 12 month low of $45.90 and a 12 month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The company had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million. During the same period last year, the firm earned ($0.72) earnings per share. The firm’s revenue was up 36.9% on a year-over-year basis. On average, equities analysts expect that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Christopher Paul German sold 5,614 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the sale, the chief accounting officer directly owned 160 shares of the company’s stock, valued at $14,329.60. This represents a 97.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 27,267 shares of company stock worth $2,719,955 in the last ninety days. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RYTM. EverSource Wealth Advisors LLC raised its position in shares of Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC raised its holdings in Rhythm Pharmaceuticals by 97.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after acquiring an additional 141 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after acquiring an additional 322 shares in the last quarter. Optiver Holding B.V. lifted its position in shares of Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its holdings in shares of Rhythm Pharmaceuticals by 73.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after acquiring an additional 145 shares during the period.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company reported strong commercial momentum and an earnings beat: FY25 revenue grew ~50% to $194.8M driven by IMCIVREE (setmelanotide), and the Q4 results beat expectations — supporting upside ahead of the March 20 PDUFA for acquired hypothalamic obesity. FY25 revenue/PDUFA article
• Positive Sentiment: Major brokers cut price targets but kept positive ratings — signaling continued analyst conviction: Citizens Jmp to $152 (market outperform), BofA to $139 (buy), Morgan Stanley to $136 (overweight), Needham to $130 (buy); all still imply meaningful upside from current levels. Benzinga: analyst moves TickerReport: Needham note
• Neutral Sentiment: Company-hosted transcript and slide deck from the Phase 3 EMANATE topline presentation are available for review — useful for investors digging into subgroup and post‑hoc details. Seeking Alpha: transcript Seeking Alpha: slideshow
• Negative Sentiment: Topline EMANATE Phase 3: the program failed to meet pre‑specified primary endpoints in four substudies — a material clinical setback that is pressuring the stock and raising near‑term uncertainty around label expansion and commercial prospects. Reuters: trial fail
• Negative Sentiment: Company press release confirms four substudies did not meet endpoints, though post‑hoc analyses showed statistically significant BMI reductions in select heterozygous genotypes — this mixed readout keeps regulatory and commercial outcomes uncertain. GlobeNewswire: EMANATE topline

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.